# 1 Estimating historical impacts of vaccination against influenza B/Yamagata in the United States

## 2 to inform possible risks of re-emergence in the absence of vaccination.

Sinead E. Morris<sup>a,b,\*</sup>, Sarabeth M. Mathis<sup>a</sup>, Jessie R. Chung<sup>a</sup>, Brendan Flannery<sup>a</sup>, Alissa O'Halloran<sup>a</sup>,
Catherine H. Bozio<sup>a</sup>, Peng-Jun Lu<sup>c</sup>, Tammy A. Santibanez<sup>c</sup>, Peter Daly<sup>a</sup>, Angiezel Merced-Morales<sup>a</sup>, Krista
Kniss<sup>a</sup>, Alicia Budd<sup>a</sup>, Lisa A. Grohskopf<sup>a</sup>, Carrie Reed<sup>a</sup>, Matthew Biggerstaff<sup>a</sup>, A. Danielle Iuliano<sup>a</sup>

- 7 <sup>a</sup>Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA, 30329
- 8 <sup>b</sup>Goldbelt Professional Services, Chesapeake, VA, USA, 23320
- 9 <sup>c</sup>Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, GA, USA, 30329
- 10
- 11 **\*Corresponding author**: run7@cdc.gov
- 1213 Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily

14 Disclament the finance file Coster for Discours Coster to the actions and do not net

- 14 represent the views of the Centers for Disease Control and Prevention.
- 15

# 16 Abstract

- 17 Influenza B/Yamagata viruses have not been detected globally since 2020 and will be removed from U.S.
- 18 2024/25 seasonal influenza vaccines. We inferred impacts of vaccination against B/Yamagata from
- 19 2016/17–2019/20 by combining B/Yamagata prevalence data with model-based estimates of disease
- 20 burden prevented by vaccination against all influenza B viruses. B/Yamagata comprised approximately
- 21 16–22% of positive virus specimens in 2016/17 and 2017/18, compared to 1% in 2018/19 and 2019/20.
- 22 Across all seasons, we estimated that vaccination against B/Yamagata prevented 4.15 million illnesses,
- 23 58,500 hospitalizations, and 4,070 deaths, and that 22.9 million B/Yamagata-associated illnesses,
- 24 340,000 hospitalizations, and 25,100 deaths would have occurred without vaccination. Vaccination
- 25 prevented the most B/Yamagata hospitalizations among adults  $\geq$ 65 years but prevented the greatest
- 26 percentage of B/Yamagata hospitalizations among children 6 months–4 years. Our results may help
- 27 assess the potential impact if B/Yamagata were to recirculate in the absence of vaccination.
- 28
- 29 Keywords: vaccination; seasonal influenza; B/Yamagata; disease burden; vaccine-preventable burden

30

# 31 Introduction

- 32 Seasonal influenza vaccination is recommended for everyone ≥6 months who does not have
- 33 contraindications in the United States (U.S.)<sup>1</sup>. Quadrivalent seasonal influenza vaccines which include
- 34 antigens for two influenza B virus lineages, B/Yamagata and B/Victoria, have been available since 2013<sup>2</sup>.
- 35 However, B/Yamagata viruses have not been detected globally since 2020 and will be removed from U.S.

vaccines starting in the 2024/25 season (although global surveillance for B/Yamagata will continue)<sup>3</sup>.
 Understanding the historical impact of vaccination against B/Yamagata is important to help assess the
 potential public health consequences if B/Yamagata were to recirculate in the absence of vaccine mediated protection.

The U.S. Centers for Disease Control and Prevention (CDC) estimates disease burden prevented
by influenza vaccination each season using a compartmental framework that accounts for vaccine
effectiveness (VE), vaccination coverage, and time-varying risks of influenza exposure<sup>4</sup>. We have
demonstrated an extension of this framework that partitions burden prevented by vaccination between
influenza A and influenza B viruses<sup>5</sup>, and hypothesized that the latter estimates could provide insights
into the impact of vaccination against B/Yamagata when combined with information on levels of
B/Yamagata circulation.

47 To explore this, we identified information on B/Yamagata circulation in the United States for four 48 seasons preceding its disappearance (2016/17–2019/20)<sup>6</sup>. These seasons ranged in epidemic severity 49 from moderate (2016/17, 2018/19 and 2019/20) to high (2017/18)<sup>7</sup>, and in levels of B/Yamagata 50 circulation<sup>8</sup>. We then combined this information with our reported estimates of influenza-associated 51 disease burden and burden prevented by vaccination for both influenza B lineages. We estimated age-52 specific numbers of illnesses, hospitalizations, and deaths prevented by vaccination against B/Yamagata, 53 and the corresponding number that would have been caused by B/Yamagata without vaccination. Our 54 results may help inform efforts to assess potential future landscapes of influenza disease burden in the 55 context of changing influenza B epidemiology and absence of vaccine protection against B/Yamagata. 56

### 57 Methods

#### 58 Surveillance data

59 We obtained information on the prevalence of influenza B/Yamagata from 2016/17–2019/20 from CDC's 60 FluView<sup>6</sup>. These data included the weekly number of influenza-positive specimens identified by virus 61 type (influenza A or B), influenza A subtype, or influenza B lineage and reported by participating public 62 health laboratories from the World Health Organization (WHO) Collaborating Laboratories System and 63 National Respiratory and Enteric Virus Surveillance System (NREVSS). Data were available for five age 64 groups: 0-4 years, 5-17 years, 18-49 years, 50-64 years, and  $\ge 65$  years. For each season, s, and age 65 group, a, we calculated the prevalence of B/Yamagata among influenza B viruses,  $p_{a,s}$ , as the proportion 66 of all influenza B specimens with known lineage that were positive for B/Yamagata. We also calculated 67 prevalence among all influenza viruses (i.e., including influenza A viruses in addition to influenza B

viruses), as the proportion of all influenza specimens with known lineage or subtype that were positivefor B/Yamagata.

70

### 71 Framework for estimating burden prevented by vaccination for B/Yamagata

72 We previously estimated disease burden and burden prevented by vaccination for all influenza B lineages

from 2016/17–2019/20 by extending a compartmental framework developed by the CDC<sup>4,5</sup>. These

74 estimates were generated for four disease severity categories (illnesses, medically-attended illnesses,

hospitalizations, and deaths) and five age groups (6 months–4 years, 5–17 years, 18–49 years, 50–64

76 years, and  $\geq$ 65 years), and included uncertainty distributions obtained from Monte Carlo simulation.

77 For each age group (a) and season (s) we estimated disease burden and burden prevented by 78 vaccination against B/Yamagata by multiplying our previous estimates for all influenza B lineages by the 79 corresponding prevalence of B/Yamagata ( $p_{a,s}$ ). For example, if  $H_{a,s}$  is the estimated number of 80 hospitalizations attributed to influenza B for age group a in season s, the number attributable to 81 B/Yamagata was estimated as  $H_{a,s} \times p_{a,s}$ . Similarly, if  $HV_{a,s}$  is the estimated number of hospitalizations 82 prevented by vaccination against influenza B, the number prevented by vaccination against B/Yamagata 83 was estimated as  $HV_{a.s} \times p_{a.s}$ . To estimate burden that could have been caused by B/Yamagata in the 84 absence of vaccination, we added the burden attributed to B/Yamagata with the estimated burden 85 prevented by vaccination against B/Yamagata, for example,  $p_{a.s}(H_{a.s} + HV_{a.s})$ .

86 There was not a direct correspondence between the youngest age group of the B/Yamagata 87 prevalence data and the influenza B burden estimates. We therefore assumed that B/Yamagata 88 prevalence among children 0-4 years could approximate prevalence among children 6 months-4 years. 89 Given the small sample size among age groups in some seasons (Table S1), we conducted an additional 90 sensitivity analysis in which one population-wide value of B/Yamagata prevalence was applied across all 91 ages. We also assumed that VE against influenza B was approximately equal to VE against B/Yamagata, so 92 that estimates of burden prevented by vaccination against influenza B could be used to infer burden 93 prevented by vaccination against B/Yamagata.

Finally, we constructed uncertainty distributions for the B/Yamagata burden estimates. First, we generated uncertainty around estimates of B/Yamagata prevalence using a Monte Carlo simulation approach described previously<sup>9,10,11</sup>. Briefly, we assumed prevalence for each age group and season followed a Binomially distributed random variable with probability of success equal to  $p_{a,s}$ . We generated 10,000 independent samples from this distribution,  $\hat{p}_{a,s,i}$ , and multiplied these by the Monte Carlo samples previously generated for each influenza B burden estimate (for example,  $\hat{H}_{a,s,i} \times \hat{p}_{a,s,i}$ , for

- *i* in 1, 2, ... 10,000). We describe uncertainty as the 95<sup>th</sup> percentiles of the resulting distributions. All in-
- 101 text estimates are reported to three significant figures.
- 102

## 103 Results

104 B/Yamagata circulation from 2016/17–2019/20

105 The prevalence of B/Yamagata varied widely across seasons (Figure 1, Figure S1). B/Yamagata was most

- 106 prevalent in 2016/17 and 2017/18, comprising approximately 16–22% of all influenza virus specimens
- 107 with a known subtype or lineage (compared to 1% in 2018/19 and 2019/20). Among all influenza B virus
- specimens with known lineage (Table S1), there was an increase in B/Yamagata prevalence by age, and in
- 109 every season the greatest proportions of B/Yamagata positive specimens were identified among adults
- 110 50–64 years and ≥65 years (Figure 1). Overall, the 2016/17 to 2019/20 seasons captured periods of high
- 111 and low B/Yamagata circulation in addition to moderate to high epidemic severity, and thus represented
- a variety of plausible epidemiological scenarios.





Figure 1. Prevalence of influenza B/Yamagata viruses. (Top) Percentage of all influenza A and B viruses with a known subtype or lineage that were identified as influenza B. (Bottom) Percentage of all influenza B viruses with a known lineage that were identified as influenza B/Yamagata. Error bars represent 95<sup>th</sup> percentiles of the simulated uncertainty distributions.

119







estimates and error bars show 95<sup>th</sup> percentile uncertainty intervals. (C) Percentage of B/Yamagata hospitalizations
 prevented by vaccination. (D) Percentage of all influenza hospitalizations averted that were prevented by

- 125 vaccination against B/Yamagata.
- 126
- 127 Estimates of B/Yamagata burden with and without vaccination

128 Across all seasons, we estimated that 22.9 million (95<sup>th</sup> percentile uncertainty interval: 20.5–28.9 million) 129 illnesses, 10.6 million (9.47–13.3 million) medically-attended illnesses, 340,000 (285,000–486,000) 130 hospitalizations, and 25,100 (17,400–47,800) deaths would have occurred due to B/Yamagata in the 131 absence of vaccination. Of these, vaccination prevented an estimated 4.15 million (3.51–5.45 million) 132 illnesses, 2.01 million (1.68–2.65 million) medically-attended illnesses, 58,500 (40,900–91,300) 133 hospitalizations, and 4,070 (2,300–8,270) deaths. Unsurprisingly, the greatest burden and prevented 134 burden was estimated for the 2016/17 and 2017/18 seasons when B/Yamagata was most prevalent 135 (Figure 2A–B). In particular, we estimated that a total of 217,000 (169,000–334,000) hospitalizations and 136 15,900 (9,010–36,200) deaths would have occurred during 2017/18 in the absence of vaccination. 137 Among age groups, adults ≥65 years were estimated to experience the greatest burden of severe 138 disease (hospitalizations and deaths) in the absence of vaccination against B/Yamagata, with up to 139 142,000 (88,800–264,000) hospitalizations and 13,100 (5,980–34,000) deaths occurring in a single 140 season (2017/18). Results were similar when expressed as the rate of severe disease per 100,000 141 population (Figure S2). Vaccination also prevented the most severe disease among adults ≥65 years. For 142 example, in 2017/18, vaccination prevented 20,900 (6,460–46,200) hospitalizations and 1,940 (530– 143 5,550) deaths due to B/Yamagata. Conversely, vaccination generally prevented the greatest percentage 144 of B/Yamagata hospitalizations among children 6 months-4 years (22-50% across seasons; Figure 2C). 145 This corresponded to up to 11% of all influenza-associated hospitalizations among young children, 146 depending on the season (Figure 2D). Results were similar when we used one B/Yamagata prevalence 147 estimate for all age groups, rather than age-specific estimates (Figure S3). Overall, our results suggest 148 older adults may be at greatest risk of severe disease if B/Yamagata were to recirculate in the absence of 149 vaccine-mediated protection.

150

#### 151 Discussion

152 We estimated the impact of vaccination against B/Yamagata-associated outcomes by combining data on

153 B/Yamagata prevalence from 2016–2020 with estimates of influenza B-associated illnesses,

154 hospitalizations and deaths prevented by vaccination during the same period. Our estimates of burden

155 prevented by vaccination, and burden that would have occurred without vaccination, were greatest in

2016/17 and 2017/18 due to high prevalence of B/Yamagata during those seasons. For all seasons,
vaccination prevented the most severe disease among adults ≥65 years, who experienced the highest
prevalence of B/Yamagata and are at increased risk of severe complications following influenza virus
infection. In contrast, the greatest percent of severe disease was prevented among young children.
Overall, our results highlight the importance of continued B/Yamagata surveillance, and readiness to
respond to possible re-emergence, given the potential for substantial morbidity and mortality without
vaccination, particularly among groups at increased risk of severe influenza-associated complications.

163 Our estimates of the impact of vaccination in mitigating the burden of influenza B/Yamagata can 164 help inform assessments of the potential impacts if B/Yamagata were to return to circulation in the 165 absence of vaccination-mediated protection. In seasons with high circulation of B/Yamagata, we 166 estimated up to 217,000 hospitalizations and 15,900 deaths would have occurred in the absence of 167 vaccination, including up to 142,000 hospitalizations and 13,100 deaths among adults ≥65 years. Since 168 our estimates reflect disease burden in the presence of some level of population immunity to 169 B/Yamagata, which may have declined since 2020 and/or may decline with its continued absence from 170 circulation and removal from the vaccine, morbidity and mortality could be higher than we have 171 reported. However, any realized burden will depend on many factors, including the prevalence of 172 B/Yamagata relative to other influenza viruses, the strength of cross-protection induced by vaccination 173 against B/Victoria, and levels and durations of pre-existing immunity to B/Yamagata conferred through 174 prior infection or vaccination.

175 There are several limitations that should be considered in interpreting these results. First, we 176 assumed VE against all influenza B viruses was reflective of VE against influenza B/Yamagata. This was 177 likely true in 2016/17 and 2017/18 when B/Yamagata was the dominant influenza B lineage. Conversely, 178 the prevalence of B/Yamagata was so low in 2018/19 and 2019/20 that a small change in VE is unlikely to 179 have a substantial impact on our absolute estimates of burden prevented by vaccination. Second, 180 information on influenza vaccination was self-reported for adults and parent-reported for children and 181 may be subject to recall bias. However, self-reported seasonal influenza vaccination status for adults has 182 been shown to have relatively high agreement with vaccination status ascertained from medical 183 records<sup>12</sup>. Finally, we assumed all vaccinees received a formulation containing B/Yamagata. However, 184 trivalent vaccines in 2016/17–2019/20 did not include B/Yamagata and were still in use in the United States, albeit at declining levels relative to quadrivalent vaccines (for example, in 2017/18, 97% of Flu VE 185 186 Network participants aged <65 years with known vaccine type received a quadrivalent inactivated 187 vaccine)<sup>9,13–15</sup>. Data on trivalent vaccination coverage were not available for all age groups and seasons to

| 188               | directly account for this in our framework, and our estimates of burden prevented by vaccination, and  |
|-------------------|--|
| 189               | thus our estimates of burden without vaccination, may be overestimated if there was less vaccine-  |
| 190               | mediated cross-protection against B/Yamagata than we have assumed. However, our methods are also   |
| 191               | conservative in that they do not account for indirect effects of vaccination in reducing infection risks   |
| 192               | through herd immunity.   |
| 193               | We have found that vaccination against B/Yamagata prevented substantial morbidity and  |
| 194               | mortality during seasons in which the virus circulated at high levels, particularly for adults $\geq$ 65 years.  |
| 195               | Continued surveillance for B/Yamagata recirculation will be important given its potential to cause   |
| 196               | substantial morbidity and mortality in the absence of vaccination.   |
| 197               |  |
| 198               | Funding: This research did not receive any specific grant from funding agencies in the public,   |
| 199               | commercial, or not-for-profit sectors.   |
| 200               |  |
| 201               | <b>Conflicts of Interest</b> : The authors have no competing interests to declare.   |
| 202               |  |
| 203               | Author Contributions: All authors attest they meet the ICMJE criteria for authorship.  |
| 204               |  |
| 205               | Data availability statement: All data were the result of secondary analyses. The majority are publicly   |
| 206               | available and cited within in the text. A small portion are not publicly available due to privacy restrictions   |
| 207               | but are available upon reasonable request to the authors.  |
| 208               |  |
| 209               | References   |
| 210<br>211<br>212 | <ol> <li>Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the<br/>Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep Morb Mortal Wkly Rep<br/>Recomm Rep. 2010;59(RR-8):1-62.</li> </ol>                                 |
| 213<br>214<br>215 | <ol> <li>Grohskopf LA, Uyeki TM, Bresee J, Cox NJ, Shimabukuro T. Prevention and control of influenza with vaccines:<br/>recommendations of the Advisory Committee on Immunization Practices (ACIP)United States, 2012-13<br/>influenza season. MMWR Morb Mortal Wkly Rep. 2012;61(32):613-618.</li> </ol> |
| 216<br>217        | <ol> <li>CDC. Trivalent Influenza Vaccines. 2024. Accessed October 3, 2024. https://www.cdc.gov/flu/vaccine-<br/>types/trivalent.html</li> </ol>   |
| 218<br>219<br>220 | <ol> <li>Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of<br/>influenza cases averted by vaccination in the United States. <i>Vaccine</i>. 2018;36(48):7331-7337.<br/>doi:10.1016/j.vaccine.2018.10.026</li> </ol>                                 |

- 5. Morris SE, Mathis SM, Chung JR, et al. Estimating historical disease burden and the impact of vaccination by
   influenza type and subtype in the United States, 2016-2020. *medRxiv*. Published online October 28,
   2024:2024.10.25.24316040. doi:10.1101/2024.10.25.24316040
- 6. CDC. FluView Interactive. 2023. Accessed February 14, 2024. https://www.cdc.gov/fluview/overview/fluview interactive.html
- 7. CDC. Past Flu Season Severity Assessments. 2024. Accessed March 25, 2024.
   https://www.cdc.gov/flu/php/surveillance/past-seasons.html
- Paget J, Caini S, Riccio MD, Waarden W van, Meijer A. Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines? *Eurosurveillance*. 2022;27(39):2200753. doi:10.2807/1560-7917.ES.2022.27.39.2200753
- P. Rolfes MA, Flannery B, Chung JR, et al. Effects of Influenza Vaccination in the United States During the 2017–
   2018 Influenza Season. *Clin Infect Dis*. 2019;69(11):1845-1853. doi:10.1093/cid/ciz075
- 10. Kostova D, Reed C, Finelli L, et al. Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the
   United States, 2005–2011. *PLOS ONE*. 2013;8(6):e66312. doi:10.1371/journal.pone.0066312
- 11. Chung JR, Rolfes MA, Flannery B, et al. Effects of Influenza Vaccination in the United States During the 2018 2019 Influenza Season. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2020;71(8):e368-e376.
   doi:10.1093/cid/ciz1244
- 12. Rolnick SJ, Parker ED, Nordin JD, et al. Self-report compared to electronic medical record across eight adult
   vaccines: Do results vary by demographic factors? *Vaccine*. 2013;31(37):3928-3935.
   doi:10.1016/j.vaccine.2013.06.041
- 13. Flannery B, Chung JR, Monto AS, et al. Influenza Vaccine Effectiveness in the United States During the 2016–
   2017 Season. *Clin Infect Dis*. 2019;68(11):1798-1806. doi:10.1093/cid/ciy775
- 14. Grohskopf LA. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory
   Committee on Immunization Practices United States, 2019–20 Influenza Season. *MMWR Recomm Rep.* 2019;68. doi:10.15585/mmwr.rr6803a1
- 15. Grohskopf LA. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory
   Committee on Immunization Practices—United States, 2018–19 Influenza Season. *MMWR Recomm Rep.* 2018;67. doi:10.15585/mmwr.rr6703a1

249